Sibylla Biotech raises €23m Series A

The financing was led by V-Bio Ventures with participation from Seroba Life Sciences, 3B Future Health Fund, Claris Ventures, CDP Venture Capital with Evolution Fund, VI Partners, Indaco Venture Partners, as well as the company’s seed investor, Vertis SGR. Concurrent with the close of the fundraising, Ward Capoen from V-Bio, Bruno Montanari from Seroba, Ciro Spedaliere from Claris Ventures, and Marianne Bjordal from 3B Future Health Fund will join Sibylla’s Board of Directors

The company‘s small molecule degraders target a protein that transiently appears during the process of protein folding and was undruggable using other pharmacological approaches. Several preclinical candidates are currently under evaluation.  Sibylla’s novel class of Folding Interfering Degraders (FIDs) can target proteins that lack druggable pockets in their native state.

The company’s lead candidate degrades the cell cycle protein Cyclin D1 that is amplified and overexpressed in a range of cancers and which is currently considered an undruggable target. The proceeds of the Series A will allow the company to build out its pipeline of therapeutics by exploiting the protein folding simulation platform, as well as to further expand its technology to a range of therapeutic areas.

Sibylla Biotech is a spin-off company from the Italian National Institute for Nuclear Physics, the University of Trento and the University of Perugia, which co-funded the collaboration with the Telethon Foundation ETS. Vertis SGR funded the breakthrough discovery technology resulting from the collaboration, enabling the initial validation of Sibylla’s technology.